Soleus Capital Management, L.P. reported 94 positions worth $2.86B for the quarter ended Jun 30, 2026, up 17.3% on the prior quarter. It opened 21 new positions, added to 25, trimmed 40 and exited 17. Its largest holding is Krystal Biotech, Inc. at 12.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| PODD Insulet Corp | +486.5K | +86.5% | $74.07M | 5.58% |
| RIGL Rigel Pharmaceuticals Inc | +1.83M | +18,335.0% | $71.73M | 2.52% |
| INSP Inspire Medical Systems, Inc. | +1.36M | +235.1% | $60.45M | 3.01% |
| ERAS Erasca, Inc. | +2.70M | – | $49.46M | 1.73% |
| CELC Celcuity Inc. | +419.9K | +32.7% | $43.93M | 6.23% |
| PBLS Parabilis Medicines, Inc. | +1.47M | – | $40.10M | 1.4% |
| LEGN Legend Biotech Corp | +1.21M | – | $34.80M | 1.22% |
| UNH Unitedhealth Group Inc | +80.0K | – | $33.25M | 1.16% |
| PALI Palisade Bio, Inc. | +13.06M | – | $27.30M | 0.954% |
| SUPN Supernus, Inc. | +520.0K | – | $24.19M | 0.845% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TWST Twist Bioscience Corp | -1.12M | -91.5% | $115.43M | 0.376% |
| KRYS Krystal Biotech, Inc. | -213.8K | -18.5% | $79.48M | 12.2% |
| TGTX Tg Therapeutics, Inc. | -1.10M | -27.3% | $60.51M | 5.62% |
| PRAX Praxis Precision Medicines, Inc. | -153.0K | -46.3% | $51.22M | 2.08% |
| ALKS Alkermes plc. | -941.6K | -47.8% | $49.34M | 1.88% |
| VCEL Vericel Corp | -1.09M | -42.8% | $48.49M | 2.27% |
| EWTX Edgewise Therapeutics, Inc. | -999.0K | -68.9% | $40.59M | 0.64% |
| MIRM Mirum Pharmaceuticals, Inc. | -325.3K | -81.3% | $38.08M | 0.307% |
| NTRA Natera, Inc. | -118.0K | -99.2% | $32.03M | <0.01% |
| ALNY Alnylam Pharmaceuticals, Inc. | -98.6K | -74.9% | $29.68M | 0.348% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ERAS Erasca, Inc. | +2.70M | $49.46M | 1.73% |
| PBLS Parabilis Medicines, Inc. | +1.47M | $40.10M | 1.4% |
| LEGN Legend Biotech Corp | +1.21M | $34.80M | 1.22% |
| UNH Unitedhealth Group Inc | +80.0K | $33.25M | 1.16% |
| PALI Palisade Bio, Inc. | +13.06M | $27.30M | 0.954% |
| SUPN Supernus, Inc. | +520.0K | $24.19M | 0.845% |
| NVCT Nuvectis Pharma, Inc. | +1.00M | $18.39M | 0.643% |
| CAPR Capricor Therapeutics, Inc. | +761.7K | $18.34M | 0.641% |
| PRLD Prelude Therapeutics Inc | +3.38M | $18.01M | 0.629% |
| AVLN Avalyn Pharma Inc. | +419.0K | $13.79M | 0.482% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| PCVX Vaxcyte, Inc. | -385.5K | $22.40M | 0.918% |
| ICLR Icon Plc | -192.0K | $21.25M | 0.871% |
| TVTX Travere Therapeutics, Inc. | -546.0K | $16.22M | 0.665% |
| INBX Inhibrx Biosciences, Inc. | -131.0K | $8.81M | 0.361% |
| DXCM Dexcom Inc | -140.0K | $8.79M | 0.36% |
| ETON Eton Pharmaceuticals, Inc. | -166.4K | $4.11M | 0.168% |
| ARWR Arrowhead Pharmaceuticals, Inc. | -28.5K | $1.79M | 0.073% |
| CTMX CytomX Therapeutics, Inc. | -300.0K | $1.41M | 0.058% |
| COGT Cogent Biosciences, Inc. | -10.0K | $384.90K | 0.016% |
| TYRA Tyra Biosciences, Inc. | -10.0K | $383.00K | 0.016% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | KRYS Krystal Biotech, Inc. | Healthcare | 939.3K | $349.09M | 12.2% | -213.8K | -18.5% | Reduced | 3.17% |
| 2 | CELC Celcuity Inc. | Healthcare | 1.70M | $178.31M | 6.23% | +419.9K | +32.7% | Added | 3.11% |
| 3 | TGTX Tg Therapeutics, Inc. | Healthcare | 2.93M | $160.86M | 5.62% | -1.10M | -27.3% | Reduced | 1.91% |
| 4 | PODD Insulet Corp | Healthcare | 1.05M | $159.71M | 5.58% | +486.5K | +86.5% | Added | 1.51% |
| 5 | NVCR NovoCure Ltd | Healthcare | 9.91M | $150.19M | 5.25% | -579.0K | -5.5% | Reduced | 8.51% |
| 6 | UTHR UNITED THERAPEUTICS Corp | Healthcare | 225.6K | $122.23M | 4.27% | +38.4K | +20.5% | Added | 0.53% |
| 7 | INSP Inspire Medical Systems, Inc. | Healthcare | 1.93M | $86.16M | 3.01% | +1.36M | +235.1% | Added | 6.68% |
| 8 | RIGL Rigel Pharmaceuticals Inc | Healthcare | 1.84M | $72.12M | 2.52% | +1.83M | +18,335.0% | Added | 9.87% |
| 9 | ANIP Ani Pharmaceuticals Inc | Healthcare | 867.8K | $71.83M | 2.51% | +47.5K | +5.8% | Added | 3.64% |
| 10 | BBNX Beta Bionics, Inc. | Healthcare | 4.39M | $68.85M | 2.41% | +39.2K | +0.9% | Added | 9.86% |
| 11 | VCEL Vericel Corp | Healthcare | 1.46M | $64.92M | 2.27% | -1.09M | -42.8% | Reduced | 2.85% |
| 12 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 177.5K | $59.43M | 2.08% | -153.0K | -46.3% | Reduced | 0.61% |
| 13 | GERN Geron Corp | Healthcare | 42.81M | $54.80M | 1.92% | +1.30M | +3.1% | Added | 6.39% |
| 14 | ALKS Alkermes plc. | Healthcare | 1.03M | $53.93M | 1.88% | -941.6K | -47.8% | Reduced | 0.61% |
| 15 | ERAS Erasca, Inc. | Healthcare | 2.70M | $49.46M | 1.73% | +2.70M | – | New | 0.86% |
Tip. Select a row to see that position’s full history at Soleus Capital Management.
As of its Q2 2026 13F filing, Soleus Capital Management, L.P.’s five largest positions were Krystal Biotech, Inc. (KRYS) at 12.2%, Celcuity Inc. (CELC) at 6.2%, Tg Therapeutics, Inc. (TGTX) at 5.6%, Insulet Corp (PODD) at 5.6%, NovoCure Ltd (NVCR) at 5.2% of the reported portfolio.
Soleus Capital Management, L.P. reported a 13F portfolio worth $2.86B across 94 positions for Q2 2026. That is up 17.3% from the previous quarter.
Its largest purchases by value were Insulet Corp ($74.07M), Rigel Pharmaceuticals Inc ($71.73M), Inspire Medical Systems, Inc. ($60.45M). It opened 21 new positions.
Its largest sales by value were Twist Bioscience Corp ($115.43M), Krystal Biotech, Inc. ($79.48M), Tg Therapeutics, Inc. ($60.51M). It exited 17 positions entirely.
From the Form 13F-HR reports Soleus Capital Management, L.P. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.